Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jul;99(7):1217-1219.
doi: 10.1002/ajh.27362. Epub 2024 May 16.

New partners for Luspatercept in β-thalassemia

Francesca Vinchi  1   2
Affiliations
Free article
Comment

New partners for Luspatercept in β-thalassemia

Francesca Vinchi. Am J Hematol. 2024 Jul.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Vinchi F, Platzbecker U. Luspatercept: a peaceful revolution in the standard of care for myelodysplastic neoplasms. Hema. 2024;8(3):e41.
    1. Guerra A, Hamilton N, Rivera A, Demsko P, Guo S, Rivella S. Combination of a TGF‐β ligand trap (RAP‐GRL) and TMPRSS6‐ASO is superior for correcting β‐thalassemia. Am J Hematol. 2024;99(7):1300‐1312. doi:10.1002/ajh.27332
    1. Tanzi E, Di Modica SM, Bordini J, et al. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin‐receptor ligand trap RAP‐536 in β‐thalassemic mice. Am J Hematol. 2024;99(7):1313‐1325. doi:10.1002/ajh.27336
    1. Casu C, Aghajan M, Oikonomidou PR, Guo S, Monia BP, Rivella S. Combination of Tmprss6‐ ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta‐thalassemia intermedia. Haematologica. 2016;101(1):e8‐e11.
    1. Casu C, Pettinato M, Liu A, et al. Correcting β‐thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. Blood. 2020;136(17):1968‐1979.

MeSH terms

LinkOut - more resources